Arcus Biosciences, Inc. (RCUS)

NYQ – Real vaqt narxi. Valyuta: USD

29.08

+0.34 (1.20%)

Bozor ochiq: Aug 12, 2026, 11:55 AM EDT

28.74

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $28.72, which was the.

09.08.2026

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.

06.08.2026

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

06.08.2026

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to break-even earnings per share a year ago.

05.08.2026

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. "Our recent publication in Nature demonstrated our commitme.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

Arcus Biosciences Announces New Employment Inducement Grants

05.08.2026

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. "Our recent publication in Nature demonstrated our commitme.

Arcus Biosciences, Inc. (RCUS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Search stocks

Arcus Biosciences, Inc. (RCUS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update